{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.984","value":"3.71"},{"groupId":"OG001","spread":"2.142","value":"2.80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"An SSE is defined as any of the following events: new symptomatic pathological fracture, requirement for radiation therapy to relieve bone pain, spinal cord compression, or tumor-related orthopedic surgical intervention. The time to first SSE is defined as the time from the date of randomization to the first occurrence of SSE.","dispersionType":"Standard Deviation","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"MEAN","populationDescription":"Participants who experienced a symptomatic skeletal event in Part 1 of the study. SSE were not assessed in Part 2, as these participants did not have mCRPC.","reportingStatus":"POSTED","timeFrame":"Every 4 weeks throughout the study. Average duration of participation, 10 months.","title":"Part 1: Time to First Symptomatic Skeletal Event (SSE)","type":"SECONDARY","unitOfMeasure":"days"}